rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 172 173 174 175 176 ... 179 »» | Laatste | Omlaag ↓
  1. [verwijderd] 6 november 2007 16:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik MD???

    Ik laat jullie verder met rust maar niet zonder de waarschuwing af te geven dat men eerst eens moet kijken wat voor berichten er een jaar geleden zijn gedaan hier.
    Dan kan het niet anders dan tot de conclusie komen dat de geschiedenis zich herhaalt. Er zou begin 2007 product in Canada zijn en nu beginnen ze opnieuw met fase2.
    En er zou product in Ecuador verkrijgbaar zijn, is niet zo.

    een ieder die twijfelt over dat Oral-lin... zoek iemand op die verstand heeft van diabetes en die lacht je vierkant in je gezicht uit.

    kijk anders even op www.diabetes.nl

    ook daar hebben ze er nog nooit van gehoord.

    't is bij sommigen hier de vraag of ze opgelicht zijn of zelf de oplichters zijn maar Z W E N D E L is het!


  6. [verwijderd] 6 november 2007 17:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    je moet eens met mensen bij pfizer babbelen die belast waren met exubera, dan weet je precies wat de kansen zijn van zo'n inhaltie insulinetje
  13. [verwijderd] 7 november 2007 11:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pff op tijd verkocht anders was me verlies nog groter. Aandeel staat volgende week weer 1,50.

    Ik heb volgende plan, zodra er bijzonder news binnen is, kopen op 1,65 en verkopen op 1,90.
  14. [verwijderd] 7 november 2007 11:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    nee, ik hecht echt heel veel waarde aan opinies van MD, Graai en Zwaluw....
    Bij pharming hadden jullie het ook bij het rechte eind m,et jullie negatieve gebash
  15. [verwijderd] 7 november 2007 11:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    MD...riep verkopen pharming toen de koers 2,20 stond, en kijk hij zit er weer eens helemaal naast...

    en raar heh als concurrent afgeeft op oralin...hahahaha laat me niet lachen, hun middel is van de markt gehaald, vind je het gek dat ze jaloers zijn op oralin...
    Ik zou zeggen koop gnbt maar op als je er zon moeite mee hebt.
  16. [verwijderd] 7 november 2007 11:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Oralin is de toekomst

    Generex Biotechnology Receives Regulatory Approval to Sell Generex Oral-lyn in India

    Thursday, November 01, 2007




    Generex Oral-lyn Becomes First Non-Injectable Buccal Insulin Approved in India; Generex Enters Into Product Licensing & Distribution Agreement With Indian Pharmaceutical Company Shreya Life Sciences Pvt. Ltd.
    Company to Hold Conference Call at 11 a.m. Eastern Today

    WORCESTER, Mass., Nov. 1, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Generex Oral-lyn, its proprietary oral insulin spray product, has been approved for importation and commercial marketing and sale in India for the treatment of diabetes by the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India. CDSCO is responsible for authorizing marketing approval of all new pharmaceutical products in India.

    Generex Oral-lyn becomes the first non-injectable buccalinsulin approved in India. Generex Oral-lyn is delivered via the Company's proprietary RapidMist(tm) device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn does not reach the lungs.

    In connection with the approval, Generex has entered into a Product Licensing and Distribution Agreement with Shreya Life Sciences Pvt. Ltd. (http://www.shreya.co.in), a leading Indian-based pharmaceutical company. Shreya is the fourth largest distributor of insulin in the Indian insulin product market with a compound annual growth rate of 38% (per C MARC market research). Shreya has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States, and African countries. The parties are making arrangements for the expansion of extant production facilities to meet the anticipated demand for the product in India and other jurisdictions where governmental approvals are pending.

    India has a significant and growing number of people with diabetes. According to the Diabetes Atlas 2007, there are approximately 40.8 million diagnosed patients with diabetes in India. There are also an estimated 35.9 million people who have pre-diabetic conditions which, if not properly treated and managed, could lead to full-blown diabetes. Generex believes that early intervention with insulin therapy could delay the onset and progression of diabetes and its numerous complications. Generex Oral-lyn, as a convenient and pain-free alternative to insulin injections, could encourage prandial insulin therapy among those patients who presently avoid injections.

    ``This approval in a market with one of the largest numbers of patients with diabetes comes after the Indian health regulatory agency conducted a rigorous review of clinical data demonstrating the safety and efficacy of Generex Oral-lyn,'' said Anna Gluskin, Generex's President & Chief Executive Officer. ``This represents the first major jurisdiction to provide approval and offers the prospect of a new treatment paradigm for diabetes and pre-diabetic conditions. We look forward to working with Shreya to offer a safe, simple, fast, flexible, familiar, convenient, and pain-free alternative to prandial insulin injections.''

    Generex's in-house regulatory department along with Nectid Clinical Services, a Princeton, NJ based contract research company that provides clinical and regulatory consultation services in respect of the Indian market, spearheaded the regulatory effort. Indian approval was granted after a long and intensive review of the Generex Oral-lyn dossier by the Drugs Controller General (India) office. Indian government approved Generex Oral-lyn only after Generex submitted satisfactory responses to a series of regulatory interrogatories. As a result of this approval, Generex and Shreya are making preparations for the commercial launch of Generex Oral-lyn in the country in early 2008. Preparations include manufacturing scale-up, marketing plans, and post-approval clinical studies.


  18. [verwijderd] 8 november 2007 10:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Clinical Trial as Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital

    Monday, November 05, 2007



    WORCESTER, Mass., Nov. 5, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that the first prostate cancer patients had been treated with its novel peptide vaccine in a Phase I clinical trial. The trial is being conducted as an extension of a collaborative agreement between Generex's Antigen Express division and the Saint Savas Cancer Hospital. The Laikon Hospital, University of Athens will also function as a site for the trial.

    In addition to safety, the Phase I study will seek to establish specific immunological responses to the AE37 vaccine peptide in 30 patients. AE37 consists of a peptide derived from the tumor associated HER-2/neu protein that has been modified to increase its ability to stimulate T helper cells. The same vaccine peptide has recently entered Phase II clinical trials in breast cancer patients, having been shown to be safe, well-tolerated and able to generate a specific immune response in a Phase I trial in breast cancer patients. Though the current study is not designed to test efficacy, imaging and Prostate Specific Antigen (PSA) levels will be monitored in patients throughout the study to assess tumor status.

    Antigen Express has been collaborating with the laboratory of Dr. Costas Baxevanis of the Saint Savas Cancer Hospital for the past three years. Those studies have clearly shown the potential of AE37 both in stimulating T helper cells obtained from cancer patients as well as in pre-clinical animal tumor models.

    Antigen Express is focused on developing active immunotherapy products for serious diseases and unmet medical needs. Currently the company has an immunotherapeutic peptide in Phase II clinical trials for breast cancer and in Phase I trials for the potentially pandemic H5N1 avian influenza.
  20. [verwijderd] 8 november 2007 16:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    First Prostate Cancer Patients Treated in a Phase I Clinical Trial as Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital

    Monday, November 05, 2007




    WORCESTER, Mass., Nov. 5, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that the first prostate cancer patients had been treated with its novel peptide vaccine in a Phase I clinical trial. The trial is being conducted as an extension of a collaborative agreement between Generex's Antigen Express division and the Saint Savas Cancer Hospital. The Laikon Hospital, University of Athens will also function as a site for the trial.

    In addition to safety, the Phase I study will seek to establish specific immunological responses to the AE37 vaccine peptide in 30 patients. AE37 consists of a peptide derived from the tumor associated HER-2/neu protein that has been modified to increase its ability to stimulate T helper cells. The same vaccine peptide has recently entered Phase II clinical trials in breast cancer patients, having been shown to be safe, well-tolerated and able to generate a specific immune response in a Phase I trial in breast cancer patients. Though the current study is not designed to test efficacy, imaging and Prostate Specific Antigen (PSA) levels will be monitored in patients throughout the study to assess tumor status.

    Antigen Express has been collaborating with the laboratory of Dr. Costas Baxevanis of the Saint Savas Cancer Hospital for the past three years. Those studies have clearly shown the potential of AE37 both in stimulating T helper cells obtained from cancer patients as well as in pre-clinical animal tumor models.

    Antigen Express is focused on developing active immunotherapy products for serious diseases and unmet medical needs. Currently the company has an immunotherapeutic peptide in Phase II clinical trials for breast cancer and in Phase I trials for the potentially pandemic H5N1 avian influenza.

3.572 Posts
Pagina: «« 1 ... 172 173 174 175 176 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.626
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.629
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.748
Aedifica 3 914
Aegon 3.258 322.799
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.891
Agfa-Gevaert 14 2.050
Ahold 3.538 74.335
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.790
Allfunds Group 4 1.470
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 243.117
AMG 971 133.308
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.997
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.773
Arcelor Mittal 2.033 320.699
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.734
Ascencio 1 27
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 106.997
ASR Nederland 21 4.483
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.666
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392